Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Biliary Tract Neoplasms 5 Cholangiocarcinoma 4 Lymphoma, B-Cell 2 Recurrence 1 Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1 Pancreatic Neoplasms 1 Neoplasms 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Klatskin Tumor 1 Cirrhosis, Familial, with Pulmonary Hypertension 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Sorafenib 222 lenvatinib 147 Bevacizumab 131 Nivolumab 87 atezolizumab 81 pembrolizumab 74 Radiosurgery 71 durvalumab 63 sintilimab 61 Oxaliplatin 60 Fluorouracil 56 Doxorubicin 47 tislelizumab 46 apatinib 45 Radiofrequency Ablation 44 Hepatectomy 43 camrelizumab 41 Leucovorin 41 Radiotherapy 40 tremelimumab 37 Magnetic Resonance Spectroscopy 36 regorafenib 34 Capecitabine 30 Immune Checkpoint Inhibitors 29 Folfox protocol 29 Cisplatin 28 cabozantinib 26 Gemcitabine 26 Cyclophosphamide 26 Ipilimumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × gemcitabine-oxaliplatin regimen × Clear all

NCT05517239 2022-08-26

PEACH

Yonsei University

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡